Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 4/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781489 | 0.87 | ERN1 (0.61) | ERN1TTRTDP1CXCL12AR | |
| SCHEMBL6535907 | 0.84 | ERN1 (0.61) | ERN1TDP1CXCL12ARALDH1A1 | |
| SCHEMBL1054210 | 0.80 | ALDH1A1 (0.55) | ERN1TDP1ALDH1A1HPGDAOX1 | |
| SCHEMBL6535891 | 0.80 | ERN1 (0.49) | ERN1ALDH1A1AOX1 | |
| SCHEMBL6785114 | 0.77 | ERN1 (0.60) | ERN1TDP1ALDH1A1HPGDAOX1 | |
| SCHEMBL6782462 | 0.77 | ERN1 (0.58) | ERN1TDP1ALDH1A1HPGDAOX1 | |
| SCHEMBL6782227 | 0.74 | ALDH1A1 (0.47) | ERN1ACHETDP1ALDH1A1HPGD | |
| SCHEMBL6781018 | 0.74 | ERN1 (0.55) | ERN1TDP1ALDH1A1HPGDAOX1 | |
| SCHEMBL6782947 | 0.74 | ERN1 (0.49) | ERN1TDP1ALDH1A1HPGDAOX1 | |
| SCHEMBL6781294 | 0.74 | HTT (0.59) | ERN1TTRTDP1CXCL12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825208-B2 | SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | ERN1 1774/4885TTR 831/4885ACHE 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.